Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 10/20 | 0.64 |
| ▸ | RAB9A | P51151 | 10/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.64 |
| ▸ | MAPT | P10636 | 9/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.64 |
| ▸ | HTT | P42858 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 6/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.64 |
| ▸ | RELA | Q04206 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | XBP1 | P17861 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2682159 | 0.85 | PAX8 (0.67) | PAX8NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL29692738 | 0.84 | PAX8 (1.00) | PAX8NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1164645 | 0.84 | PAX8 (1.00) | PAX8NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4927052 | 0.84 | PAX8 (0.70) | PAX8NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1164644 | 0.84 | PAX8 (1.00) | PAX8NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17190844 | 0.83 | KMT2A (0.78) | PAX8NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3071331 | 0.83 | RAB9A (0.57) | PAX8NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL29033679 | 0.83 | KMT2A (0.78) | PAX8NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1547192 | 0.83 | PAX8 (0.67) | PAX8NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12706326 | 0.83 | PAX8 (0.67) | PAX8NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171635-A1 | NOVEL HYDRAZONE-BASED AND OXIME-BASED FLUORESCENT AND CHROMOPHORIC/PRO-FLUORESCENT AND PRO-CHROMOPHORIC REAGENTS AND LINKERS | SOLULINK BIOSCIENCES, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8541555-B2 | Hydrazone-based and oxime-based fluorescent and chromophoric/pro-fluorescent and pro-chromophoric reagents and linkers | SOLULINK BIOSCIENCES, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20080221343-A1 | Labeled biomolecules of chromophore or the fluorophore incorporated into the linker between a reactive linking moiety and a biotin molecule; proteins, nucleic acids | AUDAX PRIVATE DEBT LLC, AS AGENT | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221343-A1 | Labeled biomolecules of chromophore or the fluorophore incorporated into the linker between a reactive linking moiety and a biotin molecule; proteins, nucleic acids | RRP12, MRPS22, HBG2 | PAX8 2424/4885NPC1 4218/4885RAB9A 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.